User profiles for Helen L. Leavis
 | Helen LeavisVerified email at umcutrecht.nl Cited by 6296 |
Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease
…, P Hoffmann, A Jones, BK Barham, HL Leavis… - Nature …, 2016 - nature.com
Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity 1
. Herein we describe a new disease caused by high-penetrance heterozygous germline …
. Herein we describe a new disease caused by high-penetrance heterozygous germline …
Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance
HL Leavis, MJM Bonten, RJL Willems - Current opinion in microbiology, 2006 - Elsevier
Vancomycin-resistant Enterococcus faecium spread dramatically in hospital settings in the
USA in the 1990s and reached endemicity at the turn of the century. Similarly, rising …
USA in the 1990s and reached endemicity at the turn of the century. Similarly, rising …
Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS
…, A Hoischen, FL van de Veerdonk, HL Leavis… - Journal of Allergy and …, 2022 - Elsevier
Background A novel autoinflammatory syndrome was recently described in male patients
who harbored somatic mutations in the X-chromosomal UBA1 gene. These patients were …
who harbored somatic mutations in the X-chromosomal UBA1 gene. These patients were …
[HTML][HTML] Insertion sequence–driven diversification creates a globally dispersed emerging multiresistant subspecies of E. faecium
HL Leavis, RJL Willems, WJB van Wamel… - PLoS …, 2007 - journals.plos.org
Enterococcus faecium, an ubiquous colonizer of humans and animals, has evolved in the
last 15 years from an avirulent commensal to the third most frequently isolated nosocomial …
last 15 years from an avirulent commensal to the third most frequently isolated nosocomial …
A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease
Objectives The association between mutations in TNFAIP3, encoding the NF-kB regulatory
protein A20, and a new autoinflammatory disease has recently been recognised. This study …
protein A20, and a new autoinflammatory disease has recently been recognised. This study …
[HTML][HTML] CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis
…, SB Snapper, RHJ Houwen, HL Leavis… - … England Journal of …, 2017 - Mass Medical Soc
Background Studies of monogenic gastrointestinal diseases have revealed molecular pathways
critical to gut homeostasis and enabled the development of targeted therapies. Methods …
critical to gut homeostasis and enabled the development of targeted therapies. Methods …
Optimizing future treatment of enterococcal infections: attacking the biofilm?
FL Paganelli, RJ Willems, HL Leavis - Trends in microbiology, 2012 - cell.com
Enterococcus faecalis and Enterococcus faecium are among the leading causative agents of
nosocomial infections and are infamous for their resistance to many antibiotics. They cause …
nosocomial infections and are infamous for their resistance to many antibiotics. They cause …
High-Level Ciprofloxacin Resistance from Point Mutations in gyrA and parC Confined to Global Hospital-Adapted Clonal Lineage CC17 of Enterococcus faecium
To substantiate a common genetic background of ciprofloxacin-resistant Enterococcus faecium,
32 ciprofloxacin-resistant (Cip r ) and 31 ciprofloxacin-susceptible (Cip s ) isolates from …
32 ciprofloxacin-resistant (Cip r ) and 31 ciprofloxacin-susceptible (Cip s ) isolates from …
Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain …
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
